IN8bio

NASDAQ: INAB ↗$1.08 USD~$10M (microcap, August 2026) MCAP

#Acute Myeloid Leukemia #Glioblastoma #B-Cell Malignancies (CD19)#Gamma-Delta T Cell Therapy #T Cell Engagers

IN8bio is a New York-based clinical-stage biopharmaceutical company developing genetically modified gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for solid and hematologic malignancies. Lead programs include INB-100 (donor-derived γδ T cells for leukemia patients undergoing haploidentical transplant), INB-200 and INB-400 (autologous γδ T cells for glioblastoma), and INB-619, a CD19-targeting γδ T cell engager advancing into IND-enabling studies. The company reported $18.0M in cash at June 30, 2026. Co-founded in 2016 by CEO William Ho and scientific founder Dr. Lawrence Lamb.

Company Info

Sector:Biotechnology / Cell Therapy (Gamma-Delta T Cells)

Headquarters:New York, New York, USA

Founded:2016

Website:in8bio.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Expected Q3 2026 financial results and gamma-delta T cell portfolio update

Clinical Development Pipeline

INB-100

Target: Donor-derived gamma-delta T cells

Leukemia (haploidentical transplant setting)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

INB-200 / INB-400

Target: Autologous gamma-delta T cells

Glioblastoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

INB-619

Target: CD19-targeting gamma-delta T cell engager

B-cell malignancies

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

William Ho

Chief Executive Officer and Co-Founder

Dr. Lawrence Lamb, Ph.D.

Scientific Founder and Chief Scientific Officer

Careers & Job Openings

No active job listings. Check back later.